Cargando…

Soluble immune checkpoints are elevated in patients with primary biliary cholangitis

BACKGROUND: Primary biliary cholangitis (PBC) is a chronically progressive liver disease mediated by an autoimmune response. The aetiology and pathogenesis of PBC are not fully understood and may be related to immune disorders caused by genetic factors and their interaction with environmental factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiuzhu, Wang, Xiaomei, Guan, Yazhe, Wang, Liquan, Gao, Yanhang, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621234/
https://www.ncbi.nlm.nih.gov/pubmed/37915081
http://dx.doi.org/10.1186/s40001-023-01419-6
_version_ 1785130374158876672
author Gao, Xiuzhu
Wang, Xiaomei
Guan, Yazhe
Wang, Liquan
Gao, Yanhang
Niu, Junqi
author_facet Gao, Xiuzhu
Wang, Xiaomei
Guan, Yazhe
Wang, Liquan
Gao, Yanhang
Niu, Junqi
author_sort Gao, Xiuzhu
collection PubMed
description BACKGROUND: Primary biliary cholangitis (PBC) is a chronically progressive liver disease mediated by an autoimmune response. The aetiology and pathogenesis of PBC are not fully understood and may be related to immune disorders caused by genetic factors and their interaction with environmental factors. Immune checkpoints play an important role in preventing the occurrence of autoimmunity. However, the level of immune checkpoints in PBC has not been reported. Here, we aimed to identify the serum levels of soluble checkpoints in patients with PBC. METHODS: Soluble checkpoint levels were evaluated using enzyme-linked immunosorbent assay in 60 patients with PBC and 20 healthy controls (HCs). The expression of immune checkpoints was compared in liver biopsy tissue samples using immunohistochemistry. Receiver operating characteristic (ROC) curves and area under the curve (AUCs) were used to determine the diagnostic performance of soluble checkpoints and laboratory indexes between patients with PBC and HCs and patients with mild and advanced PBC. A logistic regression was performed for advanced PBC. RESULTS: sCD134, sLAG-3, sPD-1, sPD-L1, and sTIM-3 levels were significantly increased in patients with PBC compared with those in healthy controls. Additionally, the levels of sCD134, sPD-1, sPD-L1, and sTIM-3 were positively associated with disease progression. Moreover, soluble checkpoints were correlated with immunoglobulin and liver functions. ROC analyses between patients with PBC and HCs showed that the AUCs of sOX40, sPD-1, and sPD-L1 were 0.967, 0.922, and 0.971, respectively. The optimal cut-off values of sOX40, sPD-1, and sPD-L1 for PBC diagnosis were 89.15, 213.4, and 68, respectively. ROC analyses between mild and advanced patients with PBC revealed that the AUCs of sOX40 and sTIM-3 were 0.767 and 0.765, respectively. The optimal cut-off values for predicting PBC stage ≥ III were 199.45 and 361.5, respectively. In univariate analysis, age, ALB, and sOX40 were associated with advanced PBC. Further, the expression of CD134 and TIM-3 was upregulated in the liver of patients with PBC. CONCLUSIONS: Our study results indicate that the serum titer of soluble checkpoints is increased in Chinese patients with PBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01419-6.
format Online
Article
Text
id pubmed-10621234
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106212342023-11-03 Soluble immune checkpoints are elevated in patients with primary biliary cholangitis Gao, Xiuzhu Wang, Xiaomei Guan, Yazhe Wang, Liquan Gao, Yanhang Niu, Junqi Eur J Med Res Research BACKGROUND: Primary biliary cholangitis (PBC) is a chronically progressive liver disease mediated by an autoimmune response. The aetiology and pathogenesis of PBC are not fully understood and may be related to immune disorders caused by genetic factors and their interaction with environmental factors. Immune checkpoints play an important role in preventing the occurrence of autoimmunity. However, the level of immune checkpoints in PBC has not been reported. Here, we aimed to identify the serum levels of soluble checkpoints in patients with PBC. METHODS: Soluble checkpoint levels were evaluated using enzyme-linked immunosorbent assay in 60 patients with PBC and 20 healthy controls (HCs). The expression of immune checkpoints was compared in liver biopsy tissue samples using immunohistochemistry. Receiver operating characteristic (ROC) curves and area under the curve (AUCs) were used to determine the diagnostic performance of soluble checkpoints and laboratory indexes between patients with PBC and HCs and patients with mild and advanced PBC. A logistic regression was performed for advanced PBC. RESULTS: sCD134, sLAG-3, sPD-1, sPD-L1, and sTIM-3 levels were significantly increased in patients with PBC compared with those in healthy controls. Additionally, the levels of sCD134, sPD-1, sPD-L1, and sTIM-3 were positively associated with disease progression. Moreover, soluble checkpoints were correlated with immunoglobulin and liver functions. ROC analyses between patients with PBC and HCs showed that the AUCs of sOX40, sPD-1, and sPD-L1 were 0.967, 0.922, and 0.971, respectively. The optimal cut-off values of sOX40, sPD-1, and sPD-L1 for PBC diagnosis were 89.15, 213.4, and 68, respectively. ROC analyses between mild and advanced patients with PBC revealed that the AUCs of sOX40 and sTIM-3 were 0.767 and 0.765, respectively. The optimal cut-off values for predicting PBC stage ≥ III were 199.45 and 361.5, respectively. In univariate analysis, age, ALB, and sOX40 were associated with advanced PBC. Further, the expression of CD134 and TIM-3 was upregulated in the liver of patients with PBC. CONCLUSIONS: Our study results indicate that the serum titer of soluble checkpoints is increased in Chinese patients with PBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01419-6. BioMed Central 2023-11-02 /pmc/articles/PMC10621234/ /pubmed/37915081 http://dx.doi.org/10.1186/s40001-023-01419-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gao, Xiuzhu
Wang, Xiaomei
Guan, Yazhe
Wang, Liquan
Gao, Yanhang
Niu, Junqi
Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title_full Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title_fullStr Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title_full_unstemmed Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title_short Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
title_sort soluble immune checkpoints are elevated in patients with primary biliary cholangitis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621234/
https://www.ncbi.nlm.nih.gov/pubmed/37915081
http://dx.doi.org/10.1186/s40001-023-01419-6
work_keys_str_mv AT gaoxiuzhu solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis
AT wangxiaomei solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis
AT guanyazhe solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis
AT wangliquan solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis
AT gaoyanhang solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis
AT niujunqi solubleimmunecheckpointsareelevatedinpatientswithprimarybiliarycholangitis